NMDA receptors and Huntington’s disease

Biology of the NMDA Receptor

Volumn , Issue , 2008, Pages 17-40

  Fernandes, Herman B ^a   Raymond, Lynn A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85057916664     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (162)

1. Vonsattel, J.P. and DiFiglia, M., Huntington disease, J. Neuropathol. Exp. Neurol., 57, 369, 1998.
2. Huntington’s Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes, Cell, 72, 971, 1993.
3. Kremer, B. et al., A worldwide study of the Huntington’s disease mutation: the sensitivity and specificity of measuring CAG repeats, New. Engl. J. Med., 330, 1401, 1994.
4. Rubinsztein, D.C. et al., Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats, Am. J. Hum. Genet., 59, 16, 1996.
5. Tobin, A.J. and Signer, E.R., Huntington’s disease: the challenge for cell biologists, Trends Cell. Biol., 10, 531, 2000.
6. Ross, C.A., Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington’s disease and related disorders, Neuron, 35, 819, 2002.
7. Hayden, M., Huntington’s Chorea. 1981, Berlin: Springer-Verlag. 192.
8. Harper, P.S., Huntington’s Disease, 2nd ed. Harper, P.S., Ed. 1996, London: W.B. Saunders. 438.
9. Paulsen, J.S. et al., Clinical markers of early disease in persons near onset of Huntington’s disease, Neurology, 57, 658, 2001.
10. Brandt, J. et al., Trinucleotide repeat length and clinical progression in Huntington’s disease, Neurology, 46, 527, 1996.
11. Myers, R.H. et al., Factors related to onset age of Huntington disease, Am. J. Hum. Genet., 34, 481, 1982.
12. Duyao, M. et al., Trinucleotide repeat length instability and age of onset in Huntington’s disease, Nat. Genet., 4, 387, 1993.
13. Andrew, S.E. et al., The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington’s disease, Nat. Genet., 4, 398, 1993.
14. Stine, O.C. et al., Correlation between the onset age of Huntington’s disease and length of the trinucleotide repeat in IT-15, Hum. Mol. Genet., 2, 1547, 1993.
15. Brinkman, R.R. et al., The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size, Am. J. Hum. Genet., 60, 1202, 1997.
16. Graveland, G.A., Williams, R.S., and DiFiglia, M., Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease, Science, 227, 770, 1985.
17. Surmeier, D.J., Bargas, J., and Kitai, S.T., Voltage-clamp analysis of a transient potassium current in rat neostriatal neurons, Brain Res., 473, 187, 1988.
18. Vonsattel, J.P. et al., Neuropathological classification of Huntington’s disease, J. Neuropathol. Exp. Neurol., 44, 559, 1985.
19. Richfield, E.K. et al., Preferential loss of preproenkephalin versus preprotachykinin neurons from the striatum of Huntington’s disease patients, Ann. Neurol., 38, 852, 1995.
20. Ferrante, R.J. et al., Selective sparing of a class of striatal neurons in Huntington’s disease, Science, 230, 561, 1985.
21. Ferrante, R.J. et al., Morphologic and histochemical characteristics of a spared subset of striatal neurons in Huntington’s disease, J. Neuropathol. Exp. Neurol., 46, 12, 1987.
22. de la Monte, S.M., Vonsattel, J.P., and Richardson, E.P., Jr., Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington’s disease, J. Neuropathol. Exp. Neurol., 47, 516, 1988.
23. Cowan, C.M. and Raymond, L.A., Selective neuronal degeneration in Huntington’s disease, Curr. Top. Dev. Biol., 75, 25, 2006.
24. Cudkowicz, M. and Kowall, N.W., Degeneration of pyramidal projection neurons in Huntington’s disease cortex, Ann. Neurol., 27, 200, 1990.
25. Hedreen, J.C. et al., Neuronal loss in layers V and VI of cerebral cortex in Huntington’s disease, Neurosci. Lett., 133, 257, 1991.
26. Strong, TV. et al., Widespread expression of the human and rat Huntington’s disease gene in brain and nonneural tissues, Nat. Genet., 5, 259, 1993.
27. Landwehrmeyer, G.B. et al., Huntington’s disease gene: regional and cellular expression in brain of normal and affected individuals, Ann. Neurol., 37, 218, 1995.
28. Sharp, A.H. et al., Widespread expression of Huntington’s disease gene (IT15) protein product, Neuron, 14, 1065, 1995.
29. Aronin, N. et al., CAG expansion affects the expression of mutant huntingtin in the Huntington’s disease brain, Neuron, 15, 1193, 1995.
30. Choo, Y.S. et al., Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release, Hum. Mol. Genet., 13, 1407, 2004.
31. DiFiglia, M. et al., Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons, Neuron, 14, 1075, 1995.
32. Velier, J. et al., Wild-type and mutant huntingtins function in vesicle trafficking in the secretory and endocytic pathways, Exp. Neurol., 152, 34, 1998.
33. Kegel, K.B. et al., Huntingtin is present in the nucleus, interacts with the transcriptional corepressor C-terminal binding protein, and represses transcription, J. Biol. Chem, 277, 7466, 2002.
34. Nasir, J. et al., Targeted disruption of the Huntington’s disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes, Cell, 81, 811, 1995.
35. Zeitlin, S. et al., Increased apoptosis and early embryonic lethality in mice nullizy-gous for the Huntington’s disease gene homologue, Nat. Genet., 11, 155, 1995.
36. Leavitt, B.R. et al., Wild-type huntingtin reduces the cellular toxicity of mutant huntingtin in vivo, Am. J. Hum. Genet., 68, 313, 2001.
37. Monyer, H. et al., Heteromeric NMDARs: molecular and functional distinction of subtypes, Science, 256, 1217, 1992.
38. Cik, M., Chazot, P.L., and Stephenson, F.A., Expression of NMDAR1-1a (N598Q)/ NMDAR2A receptors results in decreased cell mortality, Eur. J. Pharmacol., 266, R1, 1994.
39. Anegawa, N.J. et al., Transfection of N-methyl-D-aspartate receptors in a nonneuronal cell line leads to cell death, J. Neurochem., 64, 2004, 1995.
40. Raymond, L.A. et al., Glutamate receptor ion channel properties predict vulnerability to cytotoxicity in a transfected nonneuronal cell line, Mol. Cell. Neurosci., 7, 102, 1996.
41. Anegawa, N.J. et al., N-Methyl-D-aspartate receptor mediated toxicity in nonneuronal cell lines: characterization using fluorescent measures of cell viability and reactive oxygen species production, Brain Res. Mol. Brain. Res., 77, 163, 2000.
42. Chen, N. et al., Subtype-specific enhancement of NMDAR currents by mutant huntingtin, J. Neurochem., 72, 1890, 1999.
43. Zeron, M.M. et al., Mutant huntingtin enhances excitotoxic cell death, Mol. Cell. Neurosci., 17, 41, 2001.
44. Boeckman, F.A. and Aizenman, E., Pharmacological properties of acquired exci-totoxicity in Chinese hamster ovary cells transfected with N-methyl-D-aspartate receptor subunits, J. Pharmacol. Exp. Ther., 279, 515, 1996.
45. Rameau, G.A. et al., Role of NMDAR functional domains in excitatory cell death, Neuropharmacology, 39, 2255, 2000.
46. Cepeda, C. et al., NMDAR function in mouse models of Huntington disease, J. Neurosci. Res., 66, 525, 2001.
47. Zeron, M.M. et al., Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease, Neuron, 33, 849, 2002.
48. Zeron, M.M. et al., Potentiation of NMDAR-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington’s disease, Mol. Cell. Neurosci., 25, 469, 2004.
49. Starling, A.J. et al., Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington’s disease, J. Neurosci. Res., 82, 377, 2005.
50. Mangiarini, L. et al., Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice, Cell, 87, 493, 1996.
51. Davies, S.W. et al., From neuronal inclusions to neurodegeneration: neuropathological investigation of a transgenic mouse model of Huntington’s disease, Philos. Trans. R. Soc. Lond. B. Biol. Sci., 354, 981, 1999.
52. Schilling, G. et al., Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin, Hum. Mol. Genet., 8, 397, 1999.
53. Luthi-Carter, R. et al., Decreased expression of striatal signaling genes in a mouse model of Huntington’s disease, Hum. Mol. Genet., 9, 1259, 2000.
54. Hansson, O. et al., Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene, Eur. J. Neurosci., 14, 1492, 2001.
55. MacGibbon, G.A. et al., Immediate-early gene response to methamphetamine, haloperidol, and quinolinic acid is not impaired in Huntington’s disease transgenic mice, J. Neurosci. Res., 67, 372, 2002.
56. Jarabek, B.R., Yasuda, R.P., and Wolfe, B.B., Regulation of proteins affecting NMDAR-induced excitotoxicity in a Huntington’s mouse model, Brain, 127, 505, 2004.
57. Shelbourne, P.F. et al., A Huntington’s disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice, Hum. Mol. Genet., 8, 763, 1999.
58. Wheeler, V.C. et al., Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice, Hum. Mol. Genet., 9, 503, 2000.
59. Lin, C.H. et al., Neurological abnormalities in a knock-in mouse model of Huntington’s disease, Hum. Mol. Genet., 10, 137, 2001.
60. Menalled, L.B. et al., Early motor dysfunction and striosomal distribution of huntingtin microaggregates in Huntington’s disease knock-in mice, J. Neurosci., 22, 8266, 2002.
61. Menalled, L.B. et al., Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington’s disease with 140 CAG repeats, J. Comp. Neurol, 465, 11, 2003.
62. Hodgson, J.G. et al., A YAC mouse model for Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration, Neuron, 23, 181, 1999.
63. Slow, E.J. et al., Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease, Hum. Mol. Genet., 12, 1555, 2003.
64. Reddy, P.H. et al., Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA, Nat. Genet., 20, 198, 1998.
65. Van Raamsdonk, J.M. et al., Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington’s disease, J. Neurosci, 25, 4169, 2005.
66. Sattler, R. and Tymianski, M., Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death, Mol. Neurobiol., 24, 107, 2001.
67. Mattson, M.P., Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders, Neuromolecular Med., 3, 65, 2003.
68. Dingledine, R. et al., The glutamate receptor ion channels, Pharmacol. Rev., 51, 7, 1999.
69. Ishii, T. et al., Molecular characterization of the family of the N-methyl-D-aspartate receptor subunits, J. Biol. Chem., 268, 2836, 1993.
70. Monyer, H. et al., Developmental and regional expression in the rat brain and functional properties of four NMDARs, Neuron, 12, 529, 1994.
71. Flint, A.C. et al., NR2A subunit expression shortens NMDAR synaptic currents in developing neocortex, J. Neurosci., 17, 2469, 1997.
72. Chen, N., Luo, T., and Raymond, L.A., Subtype-dependence of NMDAR channel open probability, J. Neurosci., 19, 6844, 1999.
73. Misra, C. et al., Slow deactivation kinetics of NMDARs containing NR1 and NR2D subunits in rat cerebellar Purkinje cells, J. Physiol., 525 (Pt 2), 299, 2000.
74. Akazawa, C. et al., Differential expression of five N-methyl-D-aspartate receptor subunit mRNAs in the cerebellum of developing and adult rats, J. Comp. Neurol., 347, 150, 1994.
75. Sheng, M. et al., Changing subunit composition of heteromeric NMDARs during development of rat cortex, Nature, 368, 144, 1994.
76. Li, J.H. et al. Developmental changes in localization of NMDAR subunits in primary cultures of cortical neurons, Eur. J. Neurosci., 10, 1704, 1998.
77. Chapman, D.E., Keefe, K.A., and Wilcox, K.S., Evidence for functionally distinct synaptic NMDARs in ventromedial versus dorsolateral striatum, J. Neurophysiol., 89, 69, 2003.
78. Buller, A.L. et al., The molecular basis of NMDAR subtypes: native receptor diversity is predicted by subunit composition, J. Neurosci., 14, 5471, 1994.
79. Vicini, S. et al., Functional and pharmacological differences between recombinant N-methyl-D-aspartate receptors, J. Neurophysiol., 79, 555, 1998.
80. Christie, J.M., Jane, D.E., and Monaghan, D.T., Native N-methyl-D-aspartate receptors containing NR2A and NR2B subunits have pharmacologically distinct competitive antagonist binding sites, J. Pharmacol. Exp. Ther., 292, 1169, 2000.
81. Tovar, K.R. and Westbrook, G.L., The incorporation of NMDARs with a distinct subunit composition at nascent hippocampal synapses in vitro, J. Neurosci., 19, 4180, 1999.
82. Barria, A. and Malinow, R., Subunit-specific NMDAR trafficking to synapses, Neuron, 35, 345, 2002.
83. Stocca, G. and Vicini, S., Increased contribution of NR2A subunit to synaptic NMDARs in developing rat cortical neurons, J. Physiol., 507 (Pt 1), 13, 1998.
84. Hardingham, G.E., Fukunaga, Y., and Bading, H., Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways, Nat. Neurosci., 5, 405, 2002.
85. Hardingham, G.E. and Bading, H., The yin and yang of NMDAR signalling, Trends. Neurosci., 26, 81, 2003.
86. Liu, L. et al., Role of NMDAR subtypes in governing the direction of hippocampal synaptic plasticity, Science, 304, 1021, 2004.
87. Massey, P.V. et al., Differential roles of NR2A and NR2B-containing NMDARs in cortical long-term potentiation and long-term depression, J. Neurosci., 24, 7821, 2004.
88. Liu, Y. et al., NMDAR subunits have differential roles in mediating excitotoxic neuronal death both in vitro and in vivo, J. Neurosci., 27, 2846, 2007.
89. von Engelhardt, J. et al., Excitotoxicity in vitro by NR2A- and NR2B-containing NMDARs, Neuropharmacology, 53, 10, 2007.
90. Landwehrmeyer, G.B. et al., NMDAR subunit mRNA expression by projection neurons and interneurons in rat striatum, J. Neurosci., 15, 5297, 1995.
91. Ghasemzadeh, M.B. et al., Multiplicity of glutamate receptor subunits in single striatal neurons: an RNA amplification study, Mol. Pharmacol., 49, 852, 1996.
92. Rigby, M. et al., The messenger RNAs for the N-methyl-D-aspartate receptor subunits show region-specific expression of different subunit composition in the human brain, Neuroscience, 73, 429, 1996.
93. Kuppenbender, K.D. et al., Localization of alternatively spliced NMDAR1 glutamate receptor isoforms in rat striatal neurons, J. Comp. Neurol., 415, 204, 1999.
94. Standaert, D.G. et al., Expression of NMDA glutamate receptor subunit mRNAs in neurochemically identified projection and interneurons in the striatum of the rat, Brain Res. Mol. Brain Res., 64, 11, 1999.
95. Li, L. et al., Role of NR2B-type NMDARs in selective neurodegeneration in Huntington disease, Neurobiol. Aging, 24, 1113, 2003.
96. Young, A.B. et al., NMDAR losses in putamen from patients with Huntington’s disease, Science, 241, 981, 1988.
97. Albin, R.L. et al., Striatal and nigral neuron subpopulations in rigid Huntington’s disease: implications for the functional anatomy of chorea and rigidity-akinesia, Ann. Neurol., 27, 357, 1990.
98. Albin, R.L. et al., Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington’s disease, N. Engl. J. Med., 322, 1293, 1990.
99. Ali, N.J. and Levine, M.S., Changes in expression of N-methyl-D-aspartate receptor subunits occur early in the R6/2 mouse model of Huntington’s disease, Dev. Neurosci., 28, 230, 2006.
100. Cha, J.H. et al., Altered neurotransmitter receptor expression in transgenic mouse models of Huntington’s disease, Philos. Trans. R. Soc. Lond.B. Biol. Sci., 354, 981, 1999.
101. Benn, C.L. et al., Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington’s disease, Neuroscience, 147, 354, 2007.
102. Beal, M.F. et al., Replication of the neurochemical characteristics of Huntington’s disease by quinolinic acid, Nature, 321, 168, 1986.
103. Sanberg, P.R. et al., The quinolinic acid model of Huntington’s disease: locomotor abnormalities, Exp. Neurol., 105, 45, 1989.
104. Hantraye, P. et al., A primate model of Huntington’s disease: behavioral and anatomical studies of unilateral excitotoxic lesions of the caudate-putamen in the baboon, Exp. Neurol., 108, 91, 1990.
105. Beal, M.F. et al., Chronic quinolinic acid lesions in rats closely resemble Huntington’s disease, J. Neurosci., 11, 1649, 1991.
106. Cepeda, C. et al., Differential sensitivity of medium- and large-sized striatal neurons to NMDA but not kainate receptor activation in the rat, Eur. J. Neurosci., 14, 1577, 2001.
107. DiFiglia, M., Excitotoxic injury of the neostriatum: a model for Huntington’s disease, Trends Neurosci., 13, 286, 1990.
108. Beal, M.F. et al., Neurochemical and histologic characterization of striatal excito-toxic lesions produced by the mitochondrial toxin 3-nitropropionic acid, J. Neurosci., 13, 4181, 1993.
109. Greene, J.G. et al., Inhibition of succinate dehydrogenase by malonic acid produces an “excitotoxic” lesion in rat striatum, J. Neurochem., 61, 1151, 1993.
110. Brouillet, E. et al., Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates, Proc. Natl. Acad. Sci. USA, 92, 7105, 1995.
111. Bogdanov, M.B. et al., Increased vulnerability to 3-nitropropionic acid in an animal model of Huntington’s disease, J. Neurochem., 71, 2642, 1998.
112. Andre, V.M. et al., Altered cortical glutamate receptor function in the R6/2 model of Huntington’s disease, J. Neurophysiol., 95, 2108, 2006.
113. Levine, M.S. et al., Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington’s disease, J. Neurosci. Res., 58, 515, 1999.
114. Laforet, G.A. et al., Changes in cortical and striatal neurons predict behavioral and electrophysiological abnormalities in a transgenic murine model of Huntington’s disease, J. Neurosci., 21, 9112, 2001.
115. Fan, M.M. et al., Altered NMDAR trafficking in a yeast artificial chromosome transgenic mouse model of Huntington’s disease, J. Neurosci., 27, 3768, 2007.
116. Li, L. et al., Enhanced striatal NR2B-containing N-methyl-D-aspartate receptor-mediated synaptic currents in a mouse model of Huntington disease, J. Neurophysiol., 92, 2738, 2004.
117. Sun, Y. et al., Polyglutamine-expanded huntingtin promotes sensitization of N-methyl-D-aspartate receptors via post-synaptic density 95, J. Biol. Chem., 276, 24713, 2001.
118. Song, C. et al., Expression of polyglutamine-expanded huntingtin induces tyrosine phosphorylation of N-methyl-D-aspartate receptors, J. Biol. Chem., 278, 33364, 2003.
119. Tang, T.S. et al., Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington’s disease, Proc. Natl. Acad. Sci. USA, 102, 2602, 2005.
120. Shehadeh, J. et al., Striatal neuronal apoptosis is preferentially enhanced by NMDAR activation in YAC transgenic mouse model of Huntington disease, Neurobiol. Dis., 21, 392, 2006.
121. Khodorov, B., Glutamate-induced deregulation of calcium homeostasis and mitochondrial dysfunction in mammalian central neurones, Prog. Biophys. Mol. Biol., 86, 279, 2004.
122. Nicholls, D.G., Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures, Curr. Mol. Med., 4, 149, 2004.
123. Burnashev, N. et al., Fractional calcium currents through recombinant GluR channels of the NMDA, AMPA and kainate receptor subtypes, J. Physiol., 485 (Pt 2), 403, 1995.
124. 2+ influx and reversal potentials in recombinant N-methyl-D-aspartate receptor channels, Biophys. J., 70, 2165, 1996.
125. Seong, I.S. et al., HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism, Hum. Mol. Genet., 14, 2871, 2005.
126. Tang, T.S. et al., Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1, Neuron, 39, 227, 2003.
127. Nicholls, D.G. and Ward, M.W., Mitochondrial membrane potential and neuronal glutamate excitotoxicity: mortality and millivolts, Trends. Neurosci., 23, 166, 2000.
128. Schinder, A.F. et al., Mitochondrial dysfunction is a primary event in glutamate neurotoxicity, J. Neurosci., 16, 6125, 1996.
129. Sawa, A. et al., Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization, Nat. Med., 5, 1194, 1999.
130. Panov, A.V. et al., Early mitochondrial calcium defects in Huntington’s disease are a direct effect of polyglutamines, Nat. Neurosci., 5, 731, 2002.
131. 2+ handling in Huntington’s disease striatal cells: effect of histone deacetylase inhibitors, J. Neurosci., 26, 11174, 2006.
132. White, R.J. and Reynolds, I.J., Mitochondrial depolarization in glutamate-stimulated neurons: an early signal specific to excitotoxin exposure, J. Neurosci., 16, 5688, 1996.
133. Dubinsky, J.M. and Levi, Y., Calcium-induced activation of the mitochondrial permeability transition in hippocampal neurons, J. Neurosci. Res., 53, 728, 1998.
134. Crompton, M., The mitochondrial permeability transition pore and its role in cell death, Biochem. J., 341 (Pt 2), 233, 1999.
135. Marchetti, P. et al., Mitochondrial permeability transition is a central coordinating event of apoptosis, J. Exp. Med., 184, 1155, 1996.
136. Nicholls, D.G. and Budd, S.L., Mitochondria and neuronal glutamate excitotoxicity, Biochim. Biophys. Acta., 1366, 97, 1998.
137. Brustovetsky, N. et al., Calcium-induced cytochrome c release from CNS mitochondria is associated with the permeability transition and rupture of the outer membrane, J. Neurochem., 80, 207, 2002.
138. Bernardi, P., Broekemeier, K.M., and Pfeiffer, D.R., Recent progress on regulation of the mitochondrial permeability transition pore; a cyclosporin-sensitive pore in the inner mitochondrial membrane, J. Bioenerg. Biomembr., 26, 509, 1994.
139. Petit, P.X. et al., Mitochondria and programmed cell death: back to the future, FEBS Lett, 396, 7, 1996.
140. Green, D.R. and Reed, J.C., Mitochondria and apoptosis, Science, 281, 1309, 1998.
141. Duchen, M.R., Mitochondria in health and disease: perspectives on a new mitochondrial biology, Mol. Aspects Med., 25, 365, 2004.
142. Orrenius, S., Mitochondrial regulation of apoptotic cell death, Toxicol. Lett., 149, 19, 2004.
143. Alano, C.C. et al., Mitochondrial permeability transition and calcium dynamics in striatal neurons upon intense NMDAR activation, J. Neurochem., 80, 531, 2002.
144. Peng, T.I. and Greenamyre, J.T., Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors, Mol. Pharmacol., 53, 974, 1998.
145. Sattler, R. et al., Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity, J. Neurochem., 71, 2349, 1998.
146. Brennan, W.A., Jr., Bird, E.D., and Aprille, J.R., Regional mitochondrial respiratory activity in Huntington’s disease brain, J. Neurochem., 44, 1948, 1985.
147. Beal, M.F., Aging, energy, and oxidative stress in neurodegenerative diseases, Ann. Neurol, 38, 357, 1995.
148. Gu, M. et al., Mitochondrial defect in Huntington’s disease caudate nucleus, Ann. Neurol, 39, 385, 1996.
149. Browne, S.E. et al., Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia, Ann. Neurol., 41, 646, 1997.
150. Tabrizi, S.J. et al., Biochemical abnormalities and excitotoxicity in Huntington’s disease brain, Ann. Neurol., 45, 25, 1999.
151. Benchoua, A. et al., Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated huntingtin, Mol. Biol. Cell., 17, 1652, 2006.
152. Cepeda, C. et al., Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington’s disease, J. Neurosci., 23, 961, 2003.
153. Klapstein, G.J. et al., Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington’s disease transgenic mice, J. Neurophysiol., 86, 2667, 2001.
154. Usdin, M.T. et al., Impaired synaptic plasticity in mice carrying the Huntington’s disease mutation, Hum. Mol. Genet., 8, 839, 1999.
155. Murphy, K.P. et al., Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington’s disease mutation, J. Neurosci., 20, 5115, 2000.
156. Milnerwood, A.J. et al., Early development of aberrant synaptic plasticity in a mouse model of Huntington’s disease, Hum. Mol. Genet., 15, 1690, 2006.
157. Cybulska-Klosowicz, A. et al., Impaired learning-dependent cortical plasticity in Huntington’s disease transgenic mice, Neurobiol. Dis., 17, 427, 2004.
158. Mazarakis, N.K. et al., Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington’s disease mice, J. Neurosci., 25, 3059, 2005.
159. Cummings, D.M. et al., Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington’s disease, Hum. Mol. Genet., 15, 2856, 2006.
160. Picconi, B. et al., Plastic and behavioral abnormalities in experimental Huntington’s disease: a crucial role for cholinergic interneurons, Neurobiol. Dis., 22, 143, 2006.
161. Mu, Y. et al., Activity-dependent mRNA splicing controls ER export and synaptic delivery of NMDARs, Neuron, 40, 581, 2003.
162. Fernandes, H.B. et al., Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington’s disease. J. Neurosci., 27, 13614, 2007.